MediciNova vs Spruce Biosciences
MNOV and SPRB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MNOV and SPRB compare
Spruce Biosciences is the larger company, worth 1.8 times as much as MediciNova ($124M against $68.7M).
MediciNova scores higher on the StockData Score (7 against 3 for Spruce Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MNOV | SPRB |
|---|---|---|
| Size and price | ||
| Market cap | $68.7M | $124M |
| Share price | $1.40 | $43.31 |
| Change, 1 year | −11.1% | −57.6% |
| Change, 5 years | −56.5% | −80.3% |
| Beta (5Y) | 0.39 | – |
| Employees | 6 | 8 |
| StockData Score | ||
| Total score | 7 (better) | 3 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 73.4× | – |
| P/B | 1.7× (better) | 1.9× |
| FCF yield | −14.3% | – |
| Profitability | ||
| Operating margin | −1232% | – |
| Net margin | −1127% | – |
| FCF margin | −1048% | – |
| Return on equity | −24.8% (better) | −187% |
| Return on invested capital | −78.4% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.12 (better) |
| Interest coverage | – | −21.3× |
| Current ratio | 8.75 (better) | 4.83 |
| Altman Z-score | −3.99 | −3.64 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 10.5% | 69.7% |
| Held by insiders | 12.8% | 71.7% |
| Insider net buying, 12 months | −$1.7M | – |
| Short interest, % of float | 0.66% | 65.3% |
Go deeper
- MNOV stock overview
- MNOV income statement
- MNOV valuation and score
- SPRB stock overview
- SPRB income statement
- SPRB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.